<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189253</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-62091</org_study_id>
    <secondary_id>EORTC-62091</secondary_id>
    <secondary_id>2009-014889-26</secondary_id>
    <secondary_id>EU-21059</secondary_id>
    <secondary_id>PMAR-EORTC-62091</secondary_id>
    <secondary_id>SARC-020</secondary_id>
    <nct_id>NCT01189253</nct_id>
  </id_info>
  <brief_title>Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma</brief_title>
  <official_title>TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sarcoma Alliance for Research through Collaboration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride and trabectedin,
      work in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. It is not yet known whether trabectedin is more effective than
      doxorubicin hydrochloride in treating patients with advanced or metastatic soft tissue
      sarcoma.

      PURPOSE: This randomized phase II/III trial is studying the safety of trabectedin compared
      with doxorubicin hydrochloride and to see how well they work in treating patients with
      advanced or metastatic soft tissue sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To evaluate whether trabectedin given as first-line chemotherapy for patients with
           previously untreated advanced or metastatic malignant soft tissue sarcoma prolongs
           progression-free survival as compared to doxorubicin hydrochloride.

        -  To identify and validate biomarkers (including, but not limited to, XPG, BRCA1, RAD51,
           BRCA2, ATM and CHK1) of sensitivity to trabectedin in order to allow the selection of
           patients that benefit most from trabectedin treatment. (Optional translational research)

      OUTLINE: This is a multicenter, phase IIB study followed by a phase III study. Patients are
      stratified according to institution, age at registration (&lt; 60 years old vs ≥ 60 years old),
      and presence of liver metastases (yes vs no).

        -  Phase IIB (step 1): Patients are randomized to 1 of 3 treatment arms.

             -  Arm I: Patients receive doxorubicin hydrochloride IV on day 1. Treatment repeats
                every 3 weeks for 6 courses in the absence of disease progression or unacceptable
                toxicity.

             -  Arm II: Patients receive trabectedin IV over 3 hours on day 1. Courses repeat every
                3 weeks in the absence of disease progression or unacceptable toxicity.

             -  Arm III: Patients receive trabectedin IV continuously over 24 hours on day 1.
                Courses repeat every 3 weeks in the absence of disease progression or unacceptable
                toxicity.

      At the end of step 1, the best regimen of trabectedin will be determined. Patients receiving
      the non-selected trabectedin regimen (&quot;losing arm&quot;) are offered to cross over in order to
      receive the selected regimen of trabectedin.

        -  Phase III (step 2): Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive trabectedin IV on day 1 using the preferred regimen
                determined in step 1. Courses repeat every 3 weeks in the absence of disease
                progression or unacceptable toxicity.

             -  Arm II: Patients receive doxorubicin hydrochloride IV on day 1. Treatment repeats
                every 3 weeks for 6 courses in the absence of disease progression or unacceptable
                toxicity.

      Patients complete quality of life questionnaire (EORTC QLQ-C30 version 3) at baseline, at 6,
      12, 24, and 36 weeks during study, and at the end of study.

      Tumor tissue block obtained at diagnosis may be analyzed to identify and validate biomarkers
      of sensitivity to trabectedin and for tissue microarrays.

      After completion of study therapy, patients are followed up at 1 month, every 6 or 12 weeks
      until disease progression, and every 12 weeks thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Results of step1: none of the experimental arms fulfills expectations and the study will not
    continue as a phase III.
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival as assessed by RECIST v 1.1 criteria (phase IIB and phase III)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety (phase IIB)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (phase III)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate and response duration (phase III)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile (phase III)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (phase III)</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Doxorubicin 75 mg/m² every 3 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin administered on day 1 every 3 weeks for a maximum of 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabectedin IV 3 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trabectedin administered on day 1 every 3 weeks at the dose of 1.3 mg/m² until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabectedin IV 24 hours every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trabectedin administered on day 1 every 3 weeks at the dose of 1.5 mg/m² over 24 hours until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Doxorubicin 75 mg/m² every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabectedin</intervention_name>
    <arm_group_label>Trabectedin IV 3 hours</arm_group_label>
    <arm_group_label>Trabectedin IV 24 hours every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Doxorubicin 75 mg/m² every 3 weeks</arm_group_label>
    <arm_group_label>Trabectedin IV 3 hours</arm_group_label>
    <arm_group_label>Trabectedin IV 24 hours every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Doxorubicin 75 mg/m² every 3 weeks</arm_group_label>
    <arm_group_label>Trabectedin IV 3 hours</arm_group_label>
    <arm_group_label>Trabectedin IV 24 hours every 3 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed intermediate- or high-grade malignant soft tissue sarcoma

               -  Advanced and/or metastatic disease

               -  Previously untreated disease

          -  The following tumor types are not allowed:

               -  Well-differentiated liposarcoma

               -  Embryonal rhabdomyosarcoma

               -  Chondrosarcoma (excluding extraskeletal myxoid chondrosarcoma)

               -  Osteosarcoma (excluding extraskeletal osteosarcoma)

               -  Ewing tumors/primitive neuroectodermal tumor (PNET)

               -  Gastrointestinal stromal tumors (GIST)

               -  Dermatofibrosarcoma protuberans

          -  Must have confirmed disease progression based on investigator's judgment prior to
             study enrollment

          -  Measurable disease according to RECIST v 1.1 criteria

               -  Tumor lesions situated in a previously irradiated area, or in an area subjected
                  to other loco-regional therapy, are usually not considered measurable unless
                  there has been demonstrated progression in the lesion

          -  Formalin fixed paraffin embedded tumor blocks or representative hematoxylin/eosin
             slides (preferably both) available (local histopathological diagnosis will be accepted
             for trial entry)

          -  No prior anticancer therapy for this disease

               -  No prior anthracycline

               -  Non-anthracycline therapy for nonmetastatic disease is acceptable

          -  No known history of CNS metastases or leptomeningeal tumor spread

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  Absolute neutrophil count ≥ 1.5 x 10^9/L

          -  Hemoglobin ≥ 9 g/dL

          -  Platelet count ≥ 100 x 10^9/L

          -  Bilirubin normal

          -  ALT/AST ≤ 2.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2.5 times ULN, (if alkaline phosphatase &gt; 2.5 times ULN,
             hepatic isoenzymes 5-nucleotidase and/or GGT must be within the normal range)

          -  Albumin &gt; 30 g/L

          -  Serum creatinine ≤ 1.5 times ULN

          -  Creatinine clearance ≥ 30 mL/min

          -  Creatine phosphokinase (CPK) ≤ 2.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception (double barrier method for men) 2
             weeks prior to, during, and for 3 months (women) or 5 months (men) after completion of
             study therapy

          -  LVEF normal by MUGA scan or ECHO

          -  12-lead ECG normal (without clinically significant abnormalities)

          -  None of the following unstable cardiac conditions:

               -  Congestive heart failure

               -  Angina pectoris

               -  Myocardial infarction within the past year

               -  Uncontrolled arterial hypertension, defined as BP ≥ 150/100 mm Hg despite optimal
                  medical therapy

               -  Clinically significant arrhythmias

          -  No active or uncontrolled infections or serious illnesses or medical conditions,
             including a history of any of the following:

               -  Chronic alcohol abuse

               -  Hepatitis

               -  HIV

               -  Cirrhosis

          -  No history of malignancy within the past 5 years, except soft tissue sarcoma, basal
             cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, resected
             incidental prostate cancer (staged pT2 with Gleason score ≤ 6 and postoperative PSA &lt;
             0.5 ng/mL)

               -  Patients with any history of malignancies who are disease-free for more than 5
                  years are eligible

          -  a history of malignancy and disease-free for more than 5 years

          -  No psychological, familial, sociological, or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule

          -  No concurrent alcohol consumption

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 28 days since prior and no concurrent anticancer therapy including systemic
             therapy, radiotherapy, or surgery

          -  At least 28 days since prior and no other concurrent investigational agents

          -  No concurrent phenytoin, live attenuated vaccines, or yellow fever vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nguyen Binh Bui, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James E. Butrynski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachussets General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Estabrook Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114-4199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Hematology-Oncology Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203-4239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HôPITAUX UNIVERSITAIRES BORDET-ERASME - INSTITUT JULES BORDET</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St. Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital - University Copenhagen</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois-Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>77980</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>B.P. 307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASSISTANCE PUBLIQUE - HôPITAUX DE MARSEILLE - HôPITAL DE LA TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest (Ico) - Centre Rene Gauducheau</name>
      <address>
        <city>Nantes - St. Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Krankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern Ludwig-Maximilians Univ. Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Hospital - State Health Centre</name>
      <address>
        <city>Budapest</city>
        <zip>1063</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Mc - Daniel Den Hoed Cancer Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Warsaw</city>
        <zip>02 781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nhs Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Nhs Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals Nhs Trust - City Hospital Campus</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <last_update_submitted>August 7, 2014</last_update_submitted>
  <last_update_submitted_qc>August 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>adult alveolar soft-part sarcoma</keyword>
  <keyword>adult angiosarcoma</keyword>
  <keyword>adult desmoplastic small round cell tumor</keyword>
  <keyword>adult epithelioid sarcoma</keyword>
  <keyword>adult extraskeletal chondrosarcoma</keyword>
  <keyword>adult extraskeletal osteosarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult malignant hemangiopericytoma</keyword>
  <keyword>adult malignant mesenchymoma</keyword>
  <keyword>adult neurofibrosarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

